Mirlox is a nonsteroidal anti-inflammatory agent (NSAID), which has anti-inflammatory, antipyretic and analgesic effects.
Release form and composition
Dosage form - tablets: round, flat, light yellow in color, with a dividing risk on one side (7.5 mg - 20 pieces in a blister, in a cardboard bundle 1 blister; 15 mg - 10 pieces in a blister, in a cardboard bundle 1 or 2 blisters).
The active ingredient of Mirlox is meloxicam: in 1 tablet of 7.5 or 15 mg.
Additional components: sodium citrate, crospovidone micronized, maltodextrin, corn starch, magnesium stearate, lactose.
Indications for use
Mirlox is used for symptomatic treatment in the following cases:
- Rheumatoid arthritis;
- Ankylosing spondylitis (ankylosing spondylitis).
- Severe liver failure;
- Peptic ulcer and 12 duodenal ulcer in the acute phase;
- Severe renal failure (if hemodialysis is not performed);
- Aspirin asthma;
- Age up to 15 years;
- Hypersensitivity to the drug.
Relative (requires special care and constant monitoring):
- Elderly age;
- Erosive and ulcerative lesions of the gastrointestinal tract in history;
- Chronic heart failure with symptoms of circulatory failure;
- Cirrhosis of the liver;
- Hypovolemia as a result of surgical intervention.
Dosing and Administration
Mirloks should be taken orally once a day during a meal.
Recommended daily doses depending on the indications:
- Rheumatoid arthritis: 7.5-15 mg;
- Osteoarthritis: 7.5 mg, if necessary, increase to 15 mg;
- Ankylosing spondylitis: 15 mg.
Patients with severe renal failure who are on hemodialysis are prescribed 7.5 mg per day.
- Digestive system: constipation, diarrhea, flatulence, abdominal pain, erosive and ulcerative lesions of the gastrointestinal tract, dry mouth, nausea, vomiting, increased liver enzymes, gastrointestinal bleeding (latent or overt), perforation of the stomach or intestines, esophagitis, stomatitis, colitis, hepatitis;
- Cardiovascular system: sensation of hot flashes, high blood pressure, tachycardia;
- Respiratory system: cough, exacerbation of bronchial asthma;
- Central nervous system: tinnitus, confusion, disorientation, dizziness, sleep disturbance, headache;
- Urinary system: urinary tract infection, edema, proteinuria, hematuria, renal medullary necrosis, interstitial nephritis, renal failure;
- Blood system: leukopenia, anemia, thrombocytopenia;
- Organ of vision: blurred vision, conjunctivitis;
- Dermatological and allergic reactions: increased photosensitivity, skin rash, itching, urticaria, swelling of the lips and tongue, toxic epidermal necrolysis, anaphylactoid reactions (including anaphylactic shock), erythema multiforme, allergic vasculitis;
- Other: fever.
Patients who take Meloxicam and diuretics along with Mirlox should consume enough liquid.
The drug can cause drowsiness, headaches and dizziness, so during the period of treatment it is recommended to refrain from driving and performing potentially hazardous types of work.
Possible interaction reactions in the case of simultaneous use of Mirlox with other drugs:
- Other NSAIDs, including acetylsalicylic acid: the risk of erosive-ulcerative lesions and bleeding from the gastrointestinal tract;
- Antihypertensive drugs: reducing their effectiveness;
- Methotrexate: increased side effects from the hematopoietic system (risk of developing leukopenia and anemia);
- Lithium preparations: an increase in their toxic action;
- Diuretics and cyclosporine: the risk of developing renal failure;
- Intrauterine contraceptives: reducing their effectiveness;
- Anticoagulants (ticlopidine, heparin, warfarin) and thrombolytic drugs (fibrinolysin, (streptokinase): risk of bleeding;
- Kolestiramine: an increase in its excretion through the gastrointestinal tract.
Terms and conditions of storage
Store at temperatures up to 25 ºC in a place protected from light and inaccessible to children.
Shelf life - 2 years.